United States Pulmonary Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Pulmonary Drugs Market is expected to reach at a CAGR of 4.8% during the forecast period (2024-2031), according to DataM Intelligence report.

Key Development:

United States: Recent Industry Developments

✅ In September 2025, Gilead Sciences broke ground on a new manufacturing hub in the Bay Area, marking a significant step in its $32 billion U.S. investment strategy aimed at bolstering innovation and creating high-quality jobs.

✅ In August 2025, the FDA approved BRINSUPRITM (brensocatib), the first and only oral treatment for non-cystic fibrosis bronchiectasis. This once-daily therapy addresses neutrophilic inflammation, offering a new option for over 500,000 U.S. patients.

✅ In July 2025, Insmed reported successful Phase 2 trial results for its inhaled treprostinil palmitil powder, targeting pulmonary arterial hypertension (PAH). The company plans to initiate Phase 3 trials by late 2025.

Japan: Recent Industry Developments

✅ In October 2025, Boomerang Ventures announced that its portfolio company, Respiratory Health Technologies, secured seed capital to accelerate growth in respiratory wellness. This funding will support product development and market expansion.

✅ In September 2025, Nuvation Bio received approval from Japan's Ministry of Health, Labour and Welfare for IbtrozitTM (letrectinib), a treatment for advanced ROS1-positive non-small cell lung cancer. The company anticipates a $25 million milestone payment upon reimbursement price establishment.

✅ In March 2025, Japan's Ministry of Health, Labour and Welfare granted marketing authorization for Dupixent® (dupilumab) for chronic obstructive pulmonary disease (COPD) in adults inadequately controlled with existing therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/pulmonary-drugs-market?sb

Pulmonary drugs are medications used to prevent, manage, or treat respiratory and lung-related conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. They include bronchodilators, corticosteroids, and targeted therapies to improve breathing, reduce inflammation, and enhance lung function.

Recent Mergers and acquisitions:

United States
✅ In October 2025, Merck completed a $10 billion acquisition of Verona Pharma, gaining access to Ohtuvayre®, a first-in-class inhaled therapy for chronic obstructive pulmonary disease (COPD). This strategic move enhances Merck's cardio-pulmonary portfolio and positions the company for long-term growth in respiratory treatments.

✅ In October 2025, Expedition Therapeutics raised $165 million in Series A funding to develop a once-daily pill targeting neutrophil-driven inflammation in COPD patients. This investment underscores the growing interest in innovative treatments for COPD.

✅ In October 2025, the FDA approved lurbinectedin in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy.

Japan
✅ In October 2025, Pulmovant, a clinical-stage biotechnology company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). This designation aims to expedite the development of this novel therapy for a condition with significant unmet medical need.

✅ In October 2025, Takeda entered into a license and collaboration agreement with Innovent Biologics for the development, manufacturing, and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China. IBI363 is being evaluated in non-small cell lung cancer (NSCLC) and colorectal cancers.

Key Players:

=> AstraZeneca, Circassia Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Grifols, Merck & Co., Pfizer, Regeneron Pharmaceuticals, Shanghai Sine Promod Pharmaceutical Co, Nuance Pharma Limited among others.

Growth Forecast Projected:

The Global Pulmonary Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Pulmonary Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pulmonary-drugs-market

Key Segments:

➥ By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta2-Agonists (LABA), Antihistamines, Vasodilators, Short-Acting Beta2-Agonists (SABA), Anticholinergics, Combination Drugs

➥ By Application: Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis

➥ By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, E-commerce

Regional Analysis for Pulmonary Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Pulmonary Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Pulmonary Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pulmonary-drugs-market?sb

FAQ

Q: What is the growth rate of the Pulmonary Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.